Publications by authors named "Amy DeZern"

Claim this Profile
D
DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study.
Carmelo Gurnari, Hideki Makishima, Arda Durmaz, Enrico Attardi, Ryunosuke Saiki, Amy E DeZern

Leukemia· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with highdose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy.
Jonathan A Webster, Madison Reed, Hua-Ling Tsai, Philip H Imus, Douglas B Smith, Amy E DeZern

Haematologica· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML.
Andrew D Zale, Venkata Preetam Sandeep Kaduluri, Jonathan A Webster, Mark J Levis, Ivana Gojo, Amy E DeZern

Blood Neoplasia· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Follow-Up of the Baltimore Experience with Hematopoietic Cell Transplantation for Severe Aplastic Anemia Using Post-Transplantation Cyclophosphamide.
Amy E DeZern, Marianna Zahurak, Tyler Cavin, H Pierse Byrnes, Heather J Symons

Transplant Cell Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Proposed Path to Explaining the Unexplained Anemia of Aging.
Nahed El Kassar, Amy E DeZern, Janis Abkowitz, Andrew Artz, Isabel Beerman

J Gerontol A Biol Sci Med Sci· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TEMPORARY REMOVAL: Personalized Desensitization for Donor-Specific Anti-HLA Antibodies in Allogeneic Blood or Marrow Transplantation.
Christian B Gocke, Marianna Zahurak, Ilias Sinanidis, Suraya A Berger, Javier Bolaños-Meade, Amy E Dezern

Transplant Cell Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms.
Savanah D Gisriel, Fnu Aakash, John M Bennett, Robert P Hasserjian, Sanam Loghavi, Amy E DeZern

Arch Pathol Lab Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ethical considerations for hematologic precursor conditions.
Eric C Blackstone, Lachelle D Weeks, Amy E DeZern, Gregory A Abel

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbidities.
J Preston Claiborne, Daniel Li, Hua-Ling Tsai, Gabriel Ghiaur, B Douglas Smith, Amy E DeZern

Leuk Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide-associated reversible TP53-mutated clonal hematopoiesis in plasma cell neoplasms.
Christian B Gocke, Mareike Peters, Christopher D Gocke, Syed Abbas Ali, Carol Ann Huff, Amy E DeZern

Haematologica· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myelodysplastic syndromes: Updates on Genomic Landscape, Molecular Subtypes, & Targeted Therapies.
Shirley S Mo, Amy E DeZern

Curr Hematol Malig Rep· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML.
Theodoros Karantanos, Nour Naji, Taha Ahmedna, J Peske, Xinghan Zeng, Amy DeZern

Res Sq· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Up-front alternative donor HCT in severe aplastic anemia: gaps and opportunities to translate evidence into practice.
Neel S Bhatt, Azra Borogovac, Yvonne A Efebera, Anna DeSalvo, Steven M Devine, Amy E DeZern

Blood Adv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS.
Amy E DeZern, Sylvain Thepot, Stephane de Botton, Andrea Patriarca, Dries Deeren

Blood Adv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Towards graft--host disease-free alternative donor transplant platforms for patients with acquired aplastic anemia.
Joseph H Oved, Andrea Bacigalupo, Amy E DeZern

Haematologica· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies.
Michael R Savona, Olatoyosi Odenike, Gail J Roboz, Harshad Amin, Amy E DeZern

Br J Haematol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
C-C motif chemokine receptor-like 2 promotes the interferon-γ signaling response in myeloid neoplasms with erythroid differentiation and mutated .
Nour Sabiha Naji, Sergiu Pasca, Theodora Chatzilygeroudi, Pablo Toledano-Sanz, Joseph Rimando, Amy E DeZern

Haematologica· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML.
Nour Sabiha Naji, Taha Ahmedna, J David Peske, Xinghan Zeng, Brandy Perkins, Amy E DeZern

bioRxiv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with mutant MDS/AML.
David A Sallman, Rami S Komrokji, Amy E Dezern, Marie Sebert, Guillermo Garcia-Manero

Hemasphere· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT.
Carmelo Gurnari, Marie Robin, Lionel Adès, Mahmoud Aljurf, Antonio Almeida, Amy DeZern

Blood· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML.
Guillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, Karen W L Yee, Amer M Zeidan, Amy E DeZern

Future Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025.
Peter L Greenberg, Richard M Stone, Yasmin Abaza, Aref Al-Kali, Sarah Anand, Amy E DeZern

J Natl Compr Canc Netw· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement.
Uma Borate, Kelly Pugh, Allyson Waller, Rina Li Welkie, Ying Huang, Amy E DeZern

Blood· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CCRL2 promotes the interferon-γ signaling response in myeloid neoplasms with erythroid differentiation and mutated .
Nour Sabiha Naji, Sergiu Pasca, Theodora Chatzilygeroudi, Pablo Toledano-Sanz, Joseph Rimando, Amy E DeZern

bioRxiv· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation between peripheral blood and bone marrow mutations among patients with MDS from the National MDS Study.
Amy E DeZern, Johannes B Goll, Travis L Jensen, Sridhar Nonavinkere Srivatsan, Nancy K Gillis

Blood Neoplasia· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis